| Identification | Back Directory | [Name]
Benzamide, N-(2-aminophenyl)-4-[[[2-[[(4-methoxyphenyl)sulfonyl]amino]phenyl]amino]methyl]- | [CAS]
2414046-33-4 | [Synonyms]
HDAC-IN-39
Benzamide, N-(2-aminophenyl)-4-[[[2-[[(4-methoxyphenyl)sulfonyl]amino]phenyl]amino]methyl]- | [Molecular Formula]
C27H26N4O4S | [MOL File]
2414046-33-4.mol | [Molecular Weight]
502.58 |
| Hazard Information | Back Directory | [Uses]
HDAC-IN-39 (compound 16c) is a potent HDAC inhibitor, with IC50 values of 1.07 μM (HDAC1), 1.47 μM (HDAC2), and 2.27 μM (HDAC3), respectively. HDAC-IN-39 also significantly inhibits microtubule polymerization. HDAC-IN-39 induces cell cycle arrest at the G2/M phase. HDAC-IN-39 displays promising anticancer activity against resistant cancer cells[1]. | [IC 50]
HDAC1: 1.07 μM (IC50); HDAC2: 1.47 μM (IC50); HDAC3: 2.27 μM (IC50); HDAC8: >10 μM (IC50) | [References]
[1] Wu WC, et al. Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response. Eur J Med Chem. 2020 Apr 15;192:112158. DOI:10.1016/j.ejmech.2020.112158 |
|
|